The objective of this analysis was to determine the cost-effectiveness of pregabalin compared with gabapentin in pNeP and PHN in China. Improve the mental health system by preventing human rights violations in mental health institutions in order to provide the population with access to quality psychological, social and medical care aimed at preventing self-medication with pregabalin. Consider the possibility of conducting and financing scientific research using quantitative methods and including data collection on recreational use of pregabalin in the national monitoring of the drug and alcohol situation in Ukraine. According to Duarte, N et al., state monitoring of trends in the use of psychotropic drugs is key to preventing uncontrolled dispensing and related deaths from overdose 81. Foreign colleagues also emphasise the importance of educational work with doctors 108, but no such references have been found in the scientific literature in Ukraine. Given the low awareness among users of psychoactive substances about the risks of recreational use of pregabalin and its combination with other psychoactive substances, there is a need for educational activities among this target group.
- Forest plot illustrating a significant improvement in CGI-I at the end of follow-up in the pregabalin group (A).
- Prescriptions for gabapentinoids have tripled over the past 15 years as more doctors prescribed them as “safer” alternatives to opioids.
- After reviewing the full text, 20 studies were eliminated because of duplication or not being used for GAD, resulting in 14 studies.
- The objective of this secondary analysis was to compare the effect on pain alleviation of two PGB regimes; add-on and monotherapy (PGB add-on and PGB monotherapy groups), with a therapeutic regime for NeP not including PGB (non-PGB group).
Table 2.
First, missing data had to be handled according to Cochrane guidelines to estimate standard deviations. While studies provided information in graphical form, software (WebPlotDigitizer) was used to extract the necessary data. Additionally, for some variables measured at follow-up, there was a mix of follow-ups conducted between 4 and 8 weeks, requiring adjustments to closer follow-ups. Importantly, the lack of long-term outcomes, for example, beyond 6 months, limits our complete understanding of the long-term effects of pregabalin. Furthermore, some studies did not clearly provide patient numbers in each group, hindering comparative analysis. It was not possible to compare low-dose pregabalin adverse events with SSRI/SNRIs, and some adverse events, such as weight gain, were reported in only one study, preventing their inclusion in the meta-analysis.
S2 Table. Kwiatkowski unit root test results.
Additionally, prescriptions for tramadol and acetaminophen/codeine rose by 21% and 16.1%, respectively, among these pregabalin users, suggesting a potential shift toward alternative analgesics or co-analgesics 8. Conversely, in France, where pregabalin was reclassified as a controlled substance in 2021, there was an immediate significant drop of 38,475,375 mg in total pregabalin dispensed, accompanied by a concurrent decrease in co-dispensed opioids 9. These cross-national differences may reflect variations buy lyrica uk in regulatory enforcement, prescribing habits, and the availability of alternative pain management options, underscoring the importance of country-specific approaches when implementing drug control policies. The cost per additional day of mild/no pain was calculated for both patient populations (Tables 7, 8).
Nine respondents have experience of combining pregabalin with alcohol, four respondents have experience of combining pregabalin with opioids, and two have experience of combining pregabalin with other central nervous system depressants (excluding alcohol). Six respondents have experience of combining pregabalin with marijuana, five with amphetamine-type stimulants, and five with central anticholinergics. Schematic data on the combination of pregabalin with other psychoactive substances are shown in Figure 3, with more detailed information on respondents in Appendix B. Despite its limited range of FDA-approved indications, the substance has been widely used in medicine, predominantly off-label 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, facilitated by the manufacturer’s illegal promotion of the drug 44. The FBI proved that the manufacturer had engaged in aggressive marketing and paid kickbacks to doctors for prescribing a number of drugs, including pregabalin. The case was called the most high-profile healthcare fraud case ever, and the fine imposed was the largest in US history 45.